205 related articles for article (PubMed ID: 31124485)
1. Coats disease in 351 eyes: Analysis of features and outcomes over 45 years (by decade) at a single center.
Shields CL; Udyaver S; Dalvin LA; Lim LS; Atalay HT; L Khoo CT; Mazloumi M; Shields JA
Indian J Ophthalmol; 2019 Jun; 67(6):772-783. PubMed ID: 31124485
[TBL] [Abstract][Full Text] [Related]
2. Coats Disease: Clinical Features and Outcomes by Age Category in 351 Cases.
Dalvin LA; Udyaver S; Lim LS; Mazloumi M; Atalay HT; Khoo CTL; Shields CL
J Pediatr Ophthalmol Strabismus; 2019 Sep; 56(5):288-296. PubMed ID: 31545862
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab for Coats' disease with exudative retinal detachment and risk of vitreoretinal traction.
Ramasubramanian A; Shields CL
Br J Ophthalmol; 2012 Mar; 96(3):356-9. PubMed ID: 21653215
[TBL] [Abstract][Full Text] [Related]
4. The effects of a treatment combination of anti-VEGF injections, laser coagulation and cryotherapy on patients with type 3 Coat's disease.
Li S; Deng G; Liu J; Ma Y; Lu H
BMC Ophthalmol; 2017 May; 17(1):76. PubMed ID: 28532448
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Coats' Disease With Combination Therapy of Intravitreal Bevacizumab, Laser Photocoagulation, and Sub-Tenon Corticosteroids.
Sein J; Tzu JH; Murray TG; Berrocal AM
Ophthalmic Surg Lasers Imaging Retina; 2016 May; 47(5):443-9. PubMed ID: 27183548
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal bevacizumab injections combined with laser photocoagulation for adult-onset Coats' disease.
Park S; Cho HJ; Lee DW; Kim CG; Kim JW
Graefes Arch Clin Exp Ophthalmol; 2016 Aug; 254(8):1511-1517. PubMed ID: 26631136
[TBL] [Abstract][Full Text] [Related]
7. Coats-like Exudative Vitreoretinopathy in Retinitis Pigmentosa: Ocular Manifestations and Treatment Outcomes.
Moinuddin O; Sathrasala S; Jayasundera KT; Branham KH; Chang EY; Qian CX; Recchia FM; Fahim AT; Besirli CG
Ophthalmol Retina; 2021 Jan; 5(1):86-96. PubMed ID: 32507488
[TBL] [Abstract][Full Text] [Related]
8. [Adjuvant anti-VEGF therapy in Coats' disease].
Fiorentzis M; Stavridis E; Seitz B; Viestenz A
Ophthalmologe; 2015 May; 112(5):451-4. PubMed ID: 25134462
[TBL] [Abstract][Full Text] [Related]
9. TRANSCLERAL DRAINAGE OF SUBRETINAL FLUID, ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR, AND WIDE-FIELD IMAGING-GUIDED LASER IN COATS EXUDATIVE RETINAL DETACHMENT.
Stanga PE; Jaberansari H; Bindra MS; Gil-Martinez M; Biswas S
Retina; 2016 Jan; 36(1):156-62. PubMed ID: 26355946
[TBL] [Abstract][Full Text] [Related]
10. CLINICAL CHARACTERISTICS AND TREATMENT OUTCOMES OF COATS DISEASE IN A SAUDI ARABIAN POPULATION.
Al-Qahtani AA; Almasaud JM; Ghazi NG
Retina; 2015 Oct; 35(10):2091-9. PubMed ID: 25978728
[TBL] [Abstract][Full Text] [Related]
11. Management of stage 3B Coats disease: presentation of a combined treatment modality and long-term follow-up.
Liang T; Peng J; Zhang Q; Zhu X; Xu Y; Zhao P
Graefes Arch Clin Exp Ophthalmol; 2020 Sep; 258(9):2031-2038. PubMed ID: 32474693
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Visual Outcomes in Coats' Disease: A 20-Year Experience.
Ong SS; Buckley EG; McCuen BW; Jaffe GJ; Postel EA; Mahmoud TH; Stinnett SS; Toth CA; Vajzovic L; Mruthyunjaya P
Ophthalmology; 2017 Sep; 124(9):1368-1376. PubMed ID: 28461016
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of conbercept or ranibizumab intravitreal injection combined with laser therapy for Coats' disease.
Zhang L; Ke Y; Wang W; Shi X; Hei K; Li X
Graefes Arch Clin Exp Ophthalmol; 2018 Jul; 256(7):1339-1346. PubMed ID: 29549425
[TBL] [Abstract][Full Text] [Related]
14. Risk of Tractional Retinal Detachment Following Intravitreal Bevacizumab Along with Subretinal Fluid Drainage and Cryotherapy for Stage 3B Coats' Disease.
Bhat V; D'Souza P; Shah PK; Narendran V
Middle East Afr J Ophthalmol; 2016; 23(2):208-11. PubMed ID: 27162454
[TBL] [Abstract][Full Text] [Related]
15. Combined treatment for Coats' disease: retinal laser photocoagulation combined with intravitreal bevacizumab injection was effective in two cases.
Kodama A; Sugioka K; Kusaka S; Matsumoto C; Shimomura Y
BMC Ophthalmol; 2014 Mar; 14():36. PubMed ID: 24666524
[TBL] [Abstract][Full Text] [Related]
16. Coats' disease: characteristics, management, outcome, and scleral external drainage with anterior chamber maintainer for stage 3b disease.
Yousef YA; ElRimawi AH; Nazzal RM; Qaroot AF; AlAref AH; Mohammad M; Abureesh O; Rejdak R; Nowomiejska K; Avitabile T; Toro MD; AlNawaiseh I
Medicine (Baltimore); 2020 Apr; 99(16):e19623. PubMed ID: 32311932
[TBL] [Abstract][Full Text] [Related]
17. Factors Predictive of Subretinal Fluid Resolution in Coats Disease: Analysis of 177 Eyes in 177 Patients at a Single Center.
Khoo CTL; Dalvin LA; Lim LS; Mazloumi M; Atalay HT; Udyaver S; Shields JA; Shields CL
Asia Pac J Ophthalmol (Phila); 2019; 8(4):290-297. PubMed ID: 31356365
[TBL] [Abstract][Full Text] [Related]
18. Combination treatment of pediatric coats' disease: a bicenter study in Taiwan.
Lin CJ; Chen SN; Hwang JF; Yang CM
J Pediatr Ophthalmol Strabismus; 2013; 50(6):356-62. PubMed ID: 24669373
[TBL] [Abstract][Full Text] [Related]
19. Coats disease: An overview of classification, management and outcomes.
Sen M; Shields CL; Honavar SG; Shields JA
Indian J Ophthalmol; 2019 Jun; 67(6):763-771. PubMed ID: 31124484
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Coats' disease with intravitreal bevacizumab.
Ray R; Barañano DE; Hubbard GB
Br J Ophthalmol; 2013 Mar; 97(3):272-7. PubMed ID: 23269680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
